Mass drug administration campaigns for scabies and impetigo: protocol for a systematic review and meta-analysis.

Abstract

Introduction:

Scabies is recognised as a neglected tropical disease, disproportionately affecting the most vulnerable populations around the world. Impetigo often occurs secondarily to scabies. Several studies have explored mass drug administration (MDA) programmes, with some showing positive outcomes-but a systematic evaluation of such studies is yet to be reported. The main aim of this systematic review is to generate comprehensive evidence on the effect and feasibility of MDA programmes in reducing the burden of scabies and impetigo.

Methods and analysis:

A systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. Electronic databases to be searched will include CINAHL EBSCOhost, Medline Ovid, ProQuest, Science Direct, PubMed and SCOPUS. In addition, grey literature will be explored via the Australian Institute of Health and Welfare, Australian Indigenous HealthInfoNet, Informit, OaIster database and WHO. No language restrictions will be applied. All treatment studies following an MDA protocol, including randomised/quasi-controlled trials, and prospective before-after interventional studies, will be considered. The main outcome is the change in prevalence of scabies and impetigo The Cochrane collaboration risk of bias assessment tool will be used for assessing the methodological quality of studies. A random-effect restricted maximum likelihood meta-analysis will be performed to generate pooled effect (OR) using STATA V.16. Appropriate statistical tests will be carried out to quantify heterogeneity between studies and publication bias.

Ethics and dissemination:

Ethical approval is not required since data will be extracted from published works. The findings will be communicated to the scientific community through a peer-reviewed journal publication. This systematic review will present an evidence on the effect of MDA interventions on scabies and impetigo, which is instrumental to obtain a clear understanding of the treatments widely used in these programmes.

PROSPERO registration number:

CRD42020169544.

• Authors: Pousali Ghosh, Wubshet Tesfaye, Avilasha Manandhar, Thomas Calma, Mary Bushell, Victor M Oguoma, Sam Kosari, Faye McMillan, Greg Peterson, Jackson Thomas
• Journal: BMJ paediatrics open (BMJ Paediatr Open) Vol. 5 Issue 1 Pg. e001132 ( 2021) ISSN: 2399-9772 [Electronic] England
• PMID: 34263086 (Publication Type: Journal Article)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Topics

• Australia
• Humans
• Impetigo (drug therapy)
• Mass Drug Administration
• Meta-Analysis as Topic
• Prospective Studies
• Scabies (drug therapy)
• Systematic Reviews as Topic